Q-omics provides the consensus-scored MAN2A1-DT profile across patient tissues and cancer cell-line models. MAN2A1-DT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, MAN2A1-DT is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, MAN2A1-DT RNA expression shows 14,721 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight READ, BLCA, and UVM as cancer lineages where MAN2A1-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAN2A1-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAN2A1-DT survival associations across molecular data types. MAN2A1-DT RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAN2A1-DT RNA expression–survival associations across cancer types. High MAN2A1-DT expression shows unfavorable associations in KIRP, BLCA and LUAD, but favorable associations in READ, ACC and HNSC. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for MAN2A1-DT RNA expression.
This table summarizes MAN2A1-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MAN2A1-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAN2A1-DT shows lower tumor expression in BLCA, COAD, UCEC, BRCA and LUAD and higher tumor expression in KICH. The BLCA box plot shows higher MAN2A1-DT RNA expression in normal versus tumor tissue (log2 FC = −1.099, t-test p < 0.001).
This table shows molecular features associated with MAN2A1-DT in patient tissues and cancer cell lines. In patient samples, MAN2A1-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
